# Mustang Bio, Inc.: financial statements, quarterly

MBIO · Nasdaq · CIK 1680048 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mbio.md) · [Financials](/companies/mbio/financials.md) · [Filings](/companies/mbio/filings.md) · [Insiders](/companies/mbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(10.3)](/filings/0001558370-24-015048.md) | [(8.7) d](/filings/0001558370-25-003913.md) | [(5.2)](/filings/0001558370-25-007736.md) | [(8.5)](/filings/0001558370-25-010920.md) | [(1.5)](/filings/0001104659-25-108468.md) | [(1.0) d](/filings/0001104659-26-032063.md) | [(0.3)](/filings/0001104659-26-055598.md) | [(0.9)](/filings/0001104659-26-091061.md) | [(0.6)](/filings/0001104659-25-108468.md) | [(0.7) d](/filings/0001104659-26-032063.md) | [(1.1)](/filings/0001104659-26-055598.md) | [(1.2)](/filings/0001104659-26-091061.md) |
| Net income | $m | [(10.1)](/filings/0001558370-24-015048.md) | [(8.6) d](/filings/0001558370-25-003913.md) | [(5.2)](/filings/0001558370-25-007736.md) | [(8.2)](/filings/0001558370-25-010920.md) | [(1.4)](/filings/0001104659-25-108468.md) | [(1.0) d](/filings/0001104659-26-032063.md) | [(0.2)](/filings/0001104659-26-055598.md) | [(0.8)](/filings/0001104659-26-091061.md) | [(0.5)](/filings/0001104659-25-108468.md) | [(0.5) d](/filings/0001104659-26-032063.md) | [(1.0)](/filings/0001104659-26-055598.md) | [(1.1)](/filings/0001104659-26-091061.md) |
| Diluted EPS | $ per share | [(1.23)](/filings/0001558370-24-015048.md) | not reported | [(24.81)](/filings/0001558370-25-007736.md) | [(18.36)](/filings/0001558370-25-010920.md) | [(1.96)](/filings/0001104659-25-108468.md) | not reported | [(0.05)](/filings/0001104659-26-055598.md) | [(0.19)](/filings/0001104659-26-091061.md) | [(0.07)](/filings/0001104659-25-108468.md) | not reported | [(0.14)](/filings/0001104659-26-055598.md) | [(0.16)](/filings/0001104659-26-091061.md) |
| Basic EPS | $ per share | [(1.23)](/filings/0001558370-24-015048.md) | not reported | [(24.81)](/filings/0001558370-25-007736.md) | [(18.36)](/filings/0001558370-25-010920.md) | [(1.96)](/filings/0001104659-25-108468.md) | not reported | [(0.05)](/filings/0001104659-26-055598.md) | [(0.19)](/filings/0001104659-26-091061.md) | [(0.07)](/filings/0001104659-25-108468.md) | not reported | [(0.14)](/filings/0001104659-26-055598.md) | [(0.16)](/filings/0001104659-26-091061.md) |

- Revenue: not reported
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.6](/filings/0001558370-24-015048.md) | [6.2](/filings/0001558370-25-003913.md) | [1.3](/filings/0001558370-24-008283.md) | [4.3](/filings/0001558370-24-012051.md) | [3.5](/filings/0001558370-24-015048.md) | [6.8](/filings/0001104659-26-032063.md) | [14.2](/filings/0001558370-25-007736.md) | [12.7](/filings/0001558370-25-010920.md) | [19.0](/filings/0001104659-25-108468.md) | [17.3](/filings/0001104659-26-091061.md) | [16.3](/filings/0001104659-26-055598.md) | [15.2](/filings/0001104659-26-091061.md) |
| Current assets | $m | [13.6](/filings/0001558370-23-019010.md) | [11.3](/filings/0001558370-25-003913.md) | [9.2](/filings/0001558370-24-008283.md) | [7.3](/filings/0001558370-24-012051.md) | [6.1](/filings/0001558370-24-015048.md) | [8.6](/filings/0001104659-26-032063.md) | [14.9](/filings/0001558370-25-007736.md) | [13.0](/filings/0001558370-25-010920.md) | [19.4](/filings/0001104659-25-108468.md) | [17.6](/filings/0001104659-26-032063.md) | not reported | not reported |
| Total assets | $m | [20.6](/filings/0001558370-23-019010.md) | [17.7](/filings/0001558370-25-003913.md) | [14.6](/filings/0001558370-24-008283.md) | [8.5](/filings/0001558370-24-012051.md) | [7.2](/filings/0001558370-24-015048.md) | [9.3](/filings/0001104659-26-032063.md) | [14.9](/filings/0001558370-25-007736.md) | [13.0](/filings/0001558370-25-010920.md) | [19.4](/filings/0001104659-25-108468.md) | [17.6](/filings/0001104659-26-091061.md) | [16.6](/filings/0001104659-26-055598.md) | [15.6](/filings/0001104659-26-091061.md) |
| Current liabilities | $m | [14.2](/filings/0001558370-23-019010.md) | [15.4](/filings/0001558370-25-003913.md) | [17.4](/filings/0001558370-24-008283.md) | [15.9](/filings/0001558370-24-012051.md) | [15.0](/filings/0001558370-24-015048.md) | [12.6](/filings/0001104659-26-032063.md) | [11.2](/filings/0001558370-25-007736.md) | [10.0](/filings/0001558370-25-010920.md) | [9.4](/filings/0001104659-25-108468.md) | [7.9](/filings/0001104659-26-091061.md) | [7.8](/filings/0001104659-26-055598.md) | [7.9](/filings/0001104659-26-091061.md) |
| Total liabilities | $m | [16.6](/filings/0001558370-23-019010.md) | [17.6](/filings/0001558370-25-003913.md) | [19.5](/filings/0001558370-24-008283.md) | [16.8](/filings/0001558370-24-012051.md) | [15.8](/filings/0001558370-24-015048.md) | [13.2](/filings/0001104659-26-032063.md) | [11.3](/filings/0001558370-25-007736.md) | [10.2](/filings/0001558370-25-010920.md) | [9.6](/filings/0001104659-25-108468.md) | [8.1](/filings/0001104659-26-091061.md) | [8.0](/filings/0001104659-26-055598.md) | [8.1](/filings/0001104659-26-091061.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [4.0](/filings/0001558370-24-015048.md) | [0.1](/filings/0001104659-26-032063.md) | [(4.9)](/filings/0001558370-25-010920.md) | [(8.3)](/filings/0001104659-25-108468.md) | [(8.7)](/filings/0001104659-25-108468.md) | [(3.9)](/filings/0001104659-26-091061.md) | [3.6](/filings/0001104659-26-091061.md) | [2.9](/filings/0001104659-26-091061.md) | [9.8](/filings/0001104659-25-108468.md) | [9.5](/filings/0001104659-26-091061.md) | [8.6](/filings/0001104659-26-091061.md) | [7.5](/filings/0001104659-26-091061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.0) d](/filings/0001558370-24-015048.md) | [(7.3) d](/filings/0001558370-25-003913.md) | [(5.3)](/filings/0001558370-25-007736.md) | [(2.3) d](/filings/0001558370-25-010920.md) | [(1.8) d](/filings/0001104659-25-108468.md) | [(2.0) d](/filings/0001104659-26-032063.md) | [(1.4)](/filings/0001104659-26-055598.md) | [(1.3) d](/filings/0001104659-26-091061.md) | [(0.8) d](/filings/0001104659-25-108468.md) | [(1.7) d](/filings/0001104659-26-032063.md) | [(1.0)](/filings/0001104659-26-055598.md) | [(1.0) d](/filings/0001104659-26-091061.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015048.md) | [0.0 d](/filings/0001558370-25-003913.md) | not reported | not reported | [0.0 d](/filings/0001558370-24-015048.md) | [0.0 d](/filings/0001558370-25-003913.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [7,850](/filings/0001558370-23-019010.md) | [8,094](/filings/0001558370-24-008283.md) | [8,127](/filings/0001558370-24-012051.md) | [8,172](/filings/0001558370-24-015048.md) | [209](/filings/0001558370-25-007736.md) | [447](/filings/0001558370-25-010920.md) | [721](/filings/0001104659-25-108468.md) | [2,861](/filings/0001104659-26-055598.md) | [4,021](/filings/0001104659-26-091061.md) | [6,242](/filings/0001104659-25-108468.md) | [6,730](/filings/0001104659-26-055598.md) | [6,733](/filings/0001104659-26-091061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,976,289 at 2017-03-30, from the cover of the [10-K filed 2017-03-31](/filings/0001144204-17-017831.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.